Neurogenic factors are targets in depression

Drug Discovery Today: Therapeutic Strategies

Volumn 5, Issue 3, 2008, Pages 157-160

  Taupin, Philippe ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; FLUOXETINE; GLUCOCORTICOID; INTERLEUKIN 6; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; N [3 [1 [[4 (3,4 DIFLUOROPHENOXY)PHENYL]METHYL](4 PIPERIDYL)] 4 METHYLPHENYL] 2 METHYLPROPANAMIDE; SEROTONIN; STRESS HORMONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

BRAIN REGION; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG TARGETING; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 61849107452     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.09.002     Document Type: Review

References (48)

1. Eriksson P.S., et al. Neurogenesis in the adult human hippocampus. Nat. Med. 4 (1998) 1313-1317
2. Curtis M.A., et al. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 315 (2007) 1243-1249
3. Taupin P., et al. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J. Neurosci. Res. 69 (2002) 745-749
4. Taupin P. The therapeutic potential of adult neural stem cells. Curr. Opin. Mol. Ther. 8 (2006) 225-231
5. van Praag H., et al. Neural consequences of environmental enrichment. Nat. Rev. Neurosci. 1 (2000) 191-198
6. Taupin P. Adult neurogenesis in the mammalian central nervous system: functionality and potential clinical interest. Med. Sci. Monit. 11 (2005) RA247-RA252
7. Miura H., et al. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 11 (2008) 198-209
8. Gould E., et al. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3168-3171
9. Pham K., et al. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur. J. Neurosci. 17 (2003) 879-886
10. Malberg J.E., et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20 (2000) 9104-9110
11. Malberg J.E., et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28 (2003) 1562-1571
12. Banasr M., et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol. Psychiatry 59 (2006) 1087-1096
13. Perera T.D., et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J. Neurosci. 27 (2007) 4894-4901
14. Reif A., et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry 11 (2006) 514-522
15. Jacobs B.L., et al. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry 5 (2000) 262-269
16. Cameron H.A., et al. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience 61 (1994) 203-209
17. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18 (2005) 315-321
18. Vallieres L., et al. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J. Neurosci. 22 (2002) 486-492
19. Santarelli L., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
20. Groves J.O. Is it time to reassess the BDNF hypothesis of depression?. Mol. Psychiatry 12 (2007) 1079-1088
21. Siuciak J.A., et al. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56 (1997) 131-137
22. Chen B., et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50 (2001) 260-265
23. Scharfman H., et al. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp. Neurol. 192 (2005) 348-356
24. Saarelainen T., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23 (2003) 349-357
25. Duman C.H., et al. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 61 (2007) 661-670
26. Warner-Schmidt J.L., et al. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4647-4652
27. Schanzer A., et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol. 14 (2004) 237-248
28. Warner-Schmidt J.L., et al. VEGF as a potential target for therapeutic intervention in depression. Curr. Opin. Pharmacol. 8 (2008) 14-19
29. David D.J., et al. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J. Pharmacol. Exp. Ther. 321 (2007) 237-248
30. Holick K.A., et al. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33 (2008) 406-417
31. Czeh B., et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12796-12801
32. Campbell S., et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 161 (2004) 598-607
33. Colla M., et al. Hippocampal volume reduction and HPA-system activity in major depression. J. Psychiatr. Res. 41 (2007) 553-560
34. Inagaki M., et al. Hippocampal volume and first major depressive episode after cancer diagnosis in breast cancer survivors. Am. J. Psychiatry 161 (2004) 2263-2270
35. Bielau H., et al. Volume deficits of subcortical nuclei in mood disorders. A postmortem study. Eur. Arch. Psychiatry Clin. Neurosci. 255 (2005) 401-412
36. Ebmeier K.P., et al. Recent developments and current controversies in depression. Lancet 367 (2006) 153-167
37. Taupin P. Adult neurogenesis and neuroplasticity. Restor. Neurol. Neurosci. 24 (2006) 9-15
38. Taupin P. Neurogenesis and the effects of antidepressants. Drug Target Insights 1 (2006) 13-17
39. Taupin P. Adult neurogenesis pharmacology in neurological diseases and disorders. Exp. Rev. Neurother. 8 (2008) 311-320
40. Thompson A., et al. Changes in adult neurogenesis in neurodegenerative diseases: cause or consequence?. Genes Brain Behav. 7 (2008) 28-42
41. Miller M.W., et al. Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res. 457 (1988) 44-52
42. Taupin P. BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation. Brain Res. Rev. 53 (2007) 198-214
43. Taupin P. Protocols for studying adult neurogenesis: insights and recent developments. Reg. Med. 2 (2007) 51-62
44. Desai B.S., et al. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 16 (2007) 285-299
45. Ekdahl C.T., et al. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13632-13637
46. Monje M.L., et al. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302 (2003) 1760-1765
47. Kirsch I., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5 (2008) e45
48. Turner E.H., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358 (2008) 252-260